

IN THE CLAIMS

1. (currently amended) previously presented) A pharmaceutical dosage form of a combination of a high dose high solubility active ingredient, in the form of a as modified release formulation and a low dose active ingredient as an immediate release formulation suitable for swallowing; which comprises an inner portion having a low dose active ingredient as immediate release and an outer portion having a high dose, high solubility active ingredient as modified release, wherein said inner portion is covered by the outer portion from all the sides except a top surface that remains uncovered; wherein said outer portion comprises:

a) micro matrix particles containing consisting of a high dose, high solubility active ingredient and one or more hydrophobic release controlling agents wherein the weight ratio of high dose, high solubility active ingredient and hydrophobic release controlling agent is in the range of 100:2.5 to 100:30 and the low dose active ingredient is an antidiabetic drug selected from the group comprising of glibenclamide (glyburide), glipizide, gliclazide, glimepiride, tolazamide, tolbutamide, cloxpropamide, gliquidone, nateglinide, mitiglinide, glyburide, glisoxepid, glibornuride, phenbutamide, tolcyclamide, repaglinide, troglitazone, ciglitazone, rosiglitazone, pioglitazone, englitazone, acarbose, voglibose, emiglitate, miglitol, farglitazar, (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, 3-{4-[2-4-tert-butoxycarbonylaminophenyl]ethoxy}phenyl)-(S)-2-ethoxy propanoic acid and pharmaceutically acceptable salts thereof and the high dose high solubility active ingredient is an antidiabetic drug selected from the group consisting of metformin hydrochloride, phenformin and buformin,

b) a coating of one or more hydrophobic release controlling agents on said micro matrix particles, wherein the weight ratio of micromatrix particles and hydrophobic release controlling agent is in the range of 100:2.5 to 100:30.

2. (canceled)

3. (canceled)

4. (canceled)

5. (currently amended) A dosage form according to claim [[4]] 1, wherein the hydrophobic release controlling agents are selected from the group comprising of ammonio methacrylate copolymers type A and B as described in USP, methacrylic acid copolymer type A, B and C as described in USP, polyacrylate dispersion 30% as described in Ph. Eur., polyvinyl acetate dispersion, ethylcellulose, cellulose acetate, cellulose propionate (lower, medium or higher molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly(methyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), poly(hexyl methacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), waxes selected from the group consisting of beeswax, carnauba wax, microcrystalline wax, and ozokerite; fatty alcohols selected from the group consisting of cetostearyl alcohol, stearyl alcohol; cetyl alcohol and myristyl alcohol; and fatty acid esters selected from the group consisting of glyceryl monostearate, glycerol distearate, glycerol monooleate,

acetylated monoglycerides, tristearin, tripalmitin, cetyl esters wax, glyceryl palmitostearate, glyceryl behenate and hydrogenated castor oil.

6. (previously presented) A dosage form according to claim 5, wherein the hydrophobic release controlling agent(s) is selected from the group consisting of ammonio methacrylate co-polymers.

7. (previously presented) A dosage form according to claim 6, wherein the ammonio methacrylate co-polymers are selected from the group consisting of ~~Eudragit RSPO® (Ammonium Methacrylate Copolymer type B USP)~~ poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.1; Eudragit RL® (Ammonium Methacrylate Copolymer type A USP) poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.2 and ~~Eudragit NE30D® (Polyacrylate dispersion 30% Ph. Eur.)~~ poly(ethyl acrylate, methyl methacrylate) 1:1

8. (canceled)

9. (canceled)

10. (canceled)

11. (currently amended) A dosage form according to claim 1, wherein in micro matrix particles, the active ingredient and one or more hydrophobic release controlling agents are present in a weight ratio of from 100:2.5 to 100:20.

12. (previously presented) A dosage form according to claim 1, wherein said coating on said micro matrix particles

comprises one or more hydrophobic release controlling agents.

13. (previously presented) A dosage form according to claim 12, wherein the hydrophobic release controlling agents are selected from the group comprising of ammonio methacrylate copolymers type A and B as described in USP, methacrylic acid copolymer type A, B and C as described in USP, polyacrylate dispersion 30% as described in Ph. Eur., polyvinyl acetate dispersion, ethylcellulose, cellulose acetate, cellulose propionate (lower, medium or higher molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly(methyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), poly(hexyl methacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), waxes selected from the group consisting of beeswax, carnauba wax, microcrystalline wax, and ozokerite; fatty alcohols selected from the group consisting of cetostearyl alcohol, stearyl alcohol; cetyl alcohol and myristyl alcohol; and fatty acid esters selected from the group consisting of glyceryl monostearate, glycerol distearate, glycerol monooleate, acetylated monoglycerides, tristearin, tripalmitin, cetyl esters wax, glyceryl palmitostearate, glyceryl behenate glycerol distearate, and hydrogenated castor oil.

14. (currently amended) A dosage form according to claim [[13]] 1, wherein the hydrophobic release controlling agent(s) is selected from fatty acid esters.

15. (original) A dosage form according to claim 14, wherein the hydrophobic release controlling agents is selected from the group comprising of hydrogenated castor oil and glycerol distearate.

16. (canceled)

17. (canceled)

18. (currently amended) A dosage form according to claim 1, wherein in outer portion, micro matrix particles and coating of one or more hydrophobic release controlling agents are present in a weight ratio of from 100:2.5 to 100:20.

19. (original) A dosage form according to claim 1, wherein the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000.

20. (original) A dosage form according to claim 1, wherein the low dose active ingredient comprises dose less than or equal to 50 mg.
21. (canceled)
22. (canceled)
23. (previously presented) A dosage form according to claim 1, wherein the high dose, high solubility active ingredient comprises dose from 500 mg to 1500 mg.
24. (canceled)
25. (canceled)
26. (original) A dosage form according to claim 1, wherein inner portion may optionally contain more than one low dose active ingredients.
27. (original) A dosage form according to claim 1, wherein the dissolution of high dose, high solubility active ingredient is not more than 45% in 1 hour and between 25% to 90% in 6 hours.
28. (canceled)

29. (canceled)

30. (withdrawn) A process for the preparation of a dosage form as claimed in claim 1, comprising a) preparation of inner portion and b) preparation of outer portion.

31. (withdrawn) A process for the preparation of a dosage form as claimed in claim 30, wherein preparation of outer portion comprising a) preparing a micro matrix particles containing high dose, high solubility active ingredient and one or more hydrophobic release controlling agent and b) coating the said micro matrix particles containing high solubility active ingredient and one or more hydrophobic release controlling agent.

32. (original) A dosage form according to claim 1, wherein outer portion may optionally contain more than one high dose high solubility active ingredients.

33-45. (canceled)

46. (canceled)

47. (canceled)

48-51 (canceled)

52.(currently amended) A dosage form according to claim [[33]] 1, wherein the low dose antidiabetic active ingredient comprises dose less than or equal to 50 mg.

53-54 (canceled)

55 (currently amended) dosage form according to claim [[33]] 1, wherein the high dose high solubility antidiabetic active ingredient is selected from biguanides.

56. (canceled)

57.(currently amended) A dosage form according to claim [[33]] 1, wherein the high dose high solubility antidiabetic active ingredient comprises a dose from 500 mg to 1500 mg.

58.(currently amended) A dosage form according to claim [[33]] 1, is once a day oral formulation.

59. (canceled)

60.(currently amended) A dosage form according to claim [[33]] 1, wherein the high dose high solubility antidiabetic active ingredient is metformin hydrochloride.

61. (previously presented) A dosage form according to claim 60, wherein the composition of outer portion is as follows-

Micro matrix particles-

Metformin hydrochloride 75%w/w to 99%w/w

Eudragit RS® 1%w/w to 25%w/w

Coated micro matrix particles

Micro matrix particles 70%w/w to 99%w/w

Hydrogenated castor oil 1%w/w to 30%w/w

Magnesium stearate 0%w/w to 2%w/w

62. (previously presented) A dosage form according to claim 60, wherein the dissolution of metformin hydrochloride is not more than 50% in one hour, from 30 to 90 % in four hours and not less than 65 % in twelve hours.

63. (previously presented) A dosage form according to claim 60, wherein the maximum plasma metformin concentration is achieved between 700 ng/ml and 2500 ng/ml.

64. (previously presented) A dosage form according to claim 63, wherein the maximum plasma metformin concentration is achieved between 900 ng/ml and 2400 ng/ml.

65. (previously presented) A dosage form according to claim 63, wherein the maximum plasma metformin concentration is achieved between 1000 ng/ml and 2350 ng/ml.

66. (previously presented) A dosage form according to claim 60, wherein the modified release metformin hydrochloride formulations for once daily administration exhibit in vivo mean dissolution time (MDT) of 4 hours to 6 hours.

67. (previously presented) A dosage form according to claim 60, wherein the minimum plasma metformin concentration (at 24 hours) ranges between 0 and 450 ng/ml after oral administration.
68. (currently amended) A dosage form according to claim [[33]] 1, wherein the low dose antidiabetic active ingredient is rosiglitazone maleate.
69. (currently amended) A dosage form according to claim [[33]] 1, wherein the low dose antidiabetic active ingredient is glimepiride.
70. (previously presented) A dosage form as claimed in claim 60 or 68, wherein the bioavailability of rosiglitazone is not affected when it is coadministered with metformin hydrochloride.
71. (currently amended) A dosage form according to claim [[33]] 1, wherein inner portion may optionally contain more than one antidiabetic active ingredients.
72. (currently amended) A dosage form according to claim [[33]] 1, wherein the outer portion may optionally contain more than one antidiabetic active ingredients.
73. (withdrawn) A process for the preparation of a dosage form as claimed in claim 33, comprising a) preparation of inner portion and b) preparation of outer portion.

74. (withdrawn) A process for the preparation of a dosage form as claimed in claim 73, wherein preparation of outer portion comprising a) preparing a micro matrix particles containing high dose, antidiabetic active ingredient and one or more hydrophobic release controlling agent and b) coating the said micro matrix particles containing high dose antidiabetic active ingredient and one or more hydrophobic release controlling agent.

73.(new) A pharmaceutical dosage form of a combination of a high dose high solubility active ingredient, in the form of a ~~as~~ modified release formulation and a low dose active ingredient as an immediate release formulation suitable for swallowing; which comprises an inner portion having a low dose active ingredient as immediate release and an outer portion having a high dose, high solubility active ingredient as modified release, wherein said inner portion is covered by the outer portion from all the sides except a top surface that remains uncovered; wherein said outer portion consists of:

a) micro matrix particles consisting of a high dose, high solubility active ingredient and one or more hydrophobic release controlling agent wherein the weight ratio of high dose, high solubility active ingredient and hydrophobic release controlling agent is in the range of 100:2.5 to 100:30 and the low dose active ingredient is an antidiabetic drug selected from the group consisting of glibenclamide (glyburide), glipizide, gliclazide, glimepiride, tolazamide, tolbutamide, clorpropamide, gliquidone, nateglinide, glyburide, glisoxepid, glibornuride, phenbutamide, tolcyclamide, repaglinide, troglitazone, ciglitazone, pioglitazone, englitazone, acarbose, voglibose, emiglitate, miglitol, farglitazar, (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, 3-[4-[2-4-tert-butoxycarbonyl

aminophenyl)ethoxy]phenyl}-(S)-2-ethoxy propanoic acid and pharmaceutically acceptable salts thereof and the high dose high solubility active ingredient is an antidiabetic drug selected from the group consisting of metformin hydrochloride, phenformin and buformin,
b) a coating of one or more hydrophobic release controlling agents on said micro matrix particles, wherein the weight ratio of micromatrix particles and hydrophobic release controlling agent is in the range of 100:2.5 to 100:30.